This article is more than 5 years old. Information may no longer be current.

FDA clears Alleye AMD monitoring application

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has issued 510(k) clearance of Alleye, a mobile medical software application, Oculocare medical announced in a press release.

Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia, the release said.

“We are very excited about the FDA clearance, which will help millions of patients with AMD to better manage their health by monitoring their eyesight,” Lucas Bachmann, Oculocare CEO and co-founder, said in the release.

Oculocare is planning to market Alleye in the United States through pharmaceutical or medical technology partners.